Details of the Drug Combination

General Information of Drug Combination (ID: DCMMUKK)

Drug Combination Name
Triiodothyronine Azatadine
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Triiodothyronine   DM14NKM Azatadine   DMZ80SB
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 6.56
Bliss Independence Score: 6.56
Loewe Additivity Score: 21.55
LHighest Single Agent (HSA) Score: 21.55

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Triiodothyronine
Disease Entry ICD 11 Status REF
Euthyroid goiter 5A01.1 Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [3]
Indication(s) of Azatadine
Disease Entry ICD 11 Status REF
Allergic rhinitis CA08.0 Approved [4]
Common cold CA00 Approved [5]
Seasonal allergic rhinitis CA08.01 Approved [5]
Urticaria EB00-EB05 Approved [5]
Vasomotor/allergic rhinitis CA08 Approved [5]
Pruritus EC90 Investigative [5]
Azatadine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Histamine H1 receptor (H1R) TTTIBOJ HRH1_HUMAN Antagonist [6]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076923.
3 ClinicalTrials.gov (NCT04348513) Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection. U.S. National Institutes of Health.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7119).
5 Azatadine FDA Label
6 Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis. Asian Pac J Allergy Immunol. 1990 Dec;8(2):103-7.